ClinicalTrials.gg
CompletedNCT04217590DIALIZE ChinaUpdated Mar 28, 2023Results posted

Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects

A Phase 3 interventional study of Sodium Zirconium Cyclosilicate and Placebo in Hyperkalemia, sponsored by AstraZeneca. Completed at 36 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-03-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
11th of 27
134 · median 120
Started
2020
the only one that year
Phase 3
12 of 27
none open now
Registered
11th of 27
by date
Lead sponsor
16 of 27
AstraZeneca

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 12 in phase 3, and was the 11th registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic haemodialysis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study to determine the safety and efficacy of SZC in ESRD subjects with hyperkalaemia and on stable haemodialysis. This study consists of a screening period, an 8-week randomized treatment period, and a follow-up period. Approximately 134 stable haemodialysis subjects with persistent pre-dialysis hyperkalaemia will be enrolled in the study across research sites in China.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written form prior to any mandatory study specific procedures, sampling, and analyses.
  2. Subject must be ≥ 18 years of age inclusive, at the time of signing the informed consent form.
  3. Subjects must have haemodialysis access consisting of an arteriovenous fistula, AV graft, or tunnelled (permanent) catheter which is expected to remain in place for the entire duration of the study.
  4. Receiving haemodialysis (or hemodiafiltration) 3 times a week for treatment of end-stage renal disease (ESRD) for at least 3 months before randomization.
  5. Pre-dialysis S-K > 5.4 mmol/L after long inter-dialytic interval and > 5.0 mmol/L after at least one short inter-dialytic interval during screening (as assessed by central lab).
  6. Prescribed dialysate K concentration ≤ 3 mmol/L during screening.
  7. Sustained Qb ≥ 200 ml/min and spKt/V ≥ 1.2 (or URR ≥ 63) on stable haemodialysis / haemodiafltration prescription during screening with prescription (time, dialyzer, blood flow [Qb], dialysate flow rate [Qd] and bicarbonate concentration) expected to remain unchanged during study.
  8. Subjects must be receiving dietary counselling appropriate for ESRD subjects treated with haemodialysis / haemodiafiltration as per local guidelines, which includes dietary potassium restriction.

Exclusion criteria

Exclusion Criteria:

  1. Myocardial infarction, acute coronary syndrome, stroke, seizure or a thrombotic / thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 12 weeks prior to randomization.
  2. Pseudohyperkalaemia secondary to haemolyzed blood specimen (this situation is not considered screening failure, sampling or full screening can be postponed to a later time as applicable).
  3. Diagnosis of rhabdomyolysis during the 4 weeks preceding randomization.
  4. Presence of cardiac arrhythmias or conduction defects that require immediate treatment.
  5. Any medical condition, including active, infection or liver disease, that in the opinion of the investigator or Sponsor may pose a safety risk to a subject in this study, which may confound safety or efficacy assessment and jeopardize the quality of the data, or may interfere with study participation.
  6. History of associated with other medications that required discontinuation of that medication; congenital long QT syndrome or QTc(f) > 550 msec; uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication or with transient atrial fibrillation associated with dialysis or peridialytic period are permitted.
  7. Subjects treated with sodium polystyrene sulfonate (e.g. SPS, Kayexalate, Resonium), calcium polystyrene sulfonate (CPS, Resonium calcium) or patiromer (Veltassa) within 7 days before screening or anticipated in requiring any of these agents during the study.
  8. Participation in another clinical study with an product administered in the last 1 month before screening.
  9. \< 9 g/dL on screening (as assessed on Visit 1).
  10. Laboratory diagnosis of hypokalaemia (K \< 3.5 mmol/L), hypocalcemia (Ca \< 8.2 mg/d or albumin-corrected Ca \< 8.0 mg/dL if the latter is used in local practice), hypomagnesemia (Mg \< 1.7 mg/dL) or severe acidosis (serum bicarbonate 16 mEq/L or less) in the 4 weeks preceding randomization.
  11. Severe leukocytosis (> 20 × 109/L) or thrombocytosis (≥ 450 × 109/L) during screening.
  12. Polycythaemia (Hb > 14 g/dL) during screening.
  13. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  14. Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
  15. Previous randomisation in the present study.
  16. For women only - currently pregnant (confirmed with positive pregnancy test or uterine ultrasound if pregnancy test is questionable) or breast-feeding.
  17. Females of , unless using as detailed in the protocol or sexual abstinence.
  18. Lack of compliance with haemodialysis prescription (both number and duration of treatments) during the two-week period preceding screening (100% compliance required).
  19. Subjects unable to take investigational product drug mix.
  20. Scheduled date for living donor kidney transplant.
  21. Subjects with a of less than 6 months.
  22. Known or previous anaphylaxis to SZC or to components thereof.
  23. History of alcohol or drug abuse within 2 years prior to randomization.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate (SZC)

    Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.

    Drug: Sodium Zirconium Cyclosilicate

  • Placebo comparator
    Placebo

    Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.

    Drug: Placebo

Interventions

  • Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.

    Also known as: SZC; Lokelma; ZS

  • DrugPlacebo

    Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders

    A subject was considered to be a responder if, during the evaluation period, they maintained a pre-dialysis serum potassium (S-K) between 4.0 and 5.0 mmol/L on at least 3 out of 4 dialysis treatments following the long inter-dialytic interval (LIDI) and did not receive rescue therapy. Subjects with no data during the evaluation period were classified as non-responders. The S-K levels used for this analysis were based on the measurements obtained by the central laboratory.

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

Secondary outcomes

  1. Maximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period

    Probability of maintaining maximum S-K value \<= 5.5 mmol/L was evaluated. Each subject's maximum pre-dialysis S-K at long inter-dialytic interval (LIDI) and short inter-dialytic interval (SIDI) visits during the evaluation period were categorised into \<= 5.5 or \> 5.5 mmol/L. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

  2. Pre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period

    Probability of all S-K values between 3.5 and 5.5 mmol/L was evaluated. Subjects were categorised to either having all pre-dialysis LIDI values between 3.5 and 5.5 mmol/L during the evaluation period or not. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

  3. Instances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period

    The probability of maintaining instances of pre-dialysis S-K between 4.0 and 5.0 mmol/L (normokalaemia) was evaluated at each LIDI visit during the evaluation period, by categorisation of pre-dialysis S-K into values between 4.0 and 5.0 mmol/L or not. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

  4. Expected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances

    The expected number of normokalemic instances is the sum of the probabilities of normokalaemic instance at each visit during the evaluation period. Normokalaemic is defined as S-K between 4.0 and 5.0 mmol/L.

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

  5. Instances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period

    The probability of maintaining instances of potassium gradient of \< 3.0 mmol/L was evaluated at each LIDI visit during the evaluation period, by categorisation of potassium gradient into \< 3.0 or \>=3.0 mmol/L. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.

    Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.

07

Results

Posted Mar 28, 2023

Participant flow

The study has been completed and was conducted in 37 centres across China. 281 subjects were screened and 134 randomised subjects (67 per treatment group).

Participant flow — Overall Study
MilestoneSodium Zirconium Cyclosilicate (SZC)Placebo
Started6767
Completed6364
Not completed43
Withdrew: Other11
Withdrew: Withdrawal by subject31
Withdrew: Death01

Outcome measures

PrimaryPercentage of Responders

A subject was considered to be a responder if, during the evaluation period, they maintained a pre-dialysis serum potassium (S-K) between 4.0 and 5.0 mmol/L on at least 3 out of 4 dialysis treatments following the long inter-dialytic interval (LIDI) and did not receive rescue therapy. Subjects with no data during the evaluation period were classified as non-responders. The S-K levels used for this analysis were based on the measurements obtained by the central laboratory.

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Count of participants · Participants
Percentage of Responders
ParticipantsSodium Zirconium Cyclosilicate (SZC)Placebo
Percentage of Responders257
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Fisher Exact · p = <0.001 · Odds ratio (or): 5.10 · 95% CI 1.90 to 15.12The CI for OR is calculated as an exact CI. An OR \> 1 favours SZC.
SecondaryMaximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period

Probability of maintaining maximum S-K value \<= 5.5 mmol/L was evaluated. Each subject's maximum pre-dialysis S-K at long inter-dialytic interval (LIDI) and short inter-dialytic interval (SIDI) visits during the evaluation period were categorised into \<= 5.5 or \> 5.5 mmol/L. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Number · Probability
Maximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period
ProbabilitySodium Zirconium Cyclosilicate (SZC)Placebo
Maximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period0.540.15
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.41 · 95% CI 2.64 to 15.55An OR \> 1 favours SZC.
SecondaryPre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period

Probability of all S-K values between 3.5 and 5.5 mmol/L was evaluated. Subjects were categorised to either having all pre-dialysis LIDI values between 3.5 and 5.5 mmol/L during the evaluation period or not. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Number · Probability
Pre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period
ProbabilitySodium Zirconium Cyclosilicate (SZC)Placebo
Pre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period0.580.17
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.41 · 95% CI 2.71 to 15.12An OR \> 1 favours SZC.
SecondaryInstances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period

The probability of maintaining instances of pre-dialysis S-K between 4.0 and 5.0 mmol/L (normokalaemia) was evaluated at each LIDI visit during the evaluation period, by categorisation of pre-dialysis S-K into values between 4.0 and 5.0 mmol/L or not. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Number · Probability
Instances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period
ProbabilitySodium Zirconium Cyclosilicate (SZC)Placebo
Instances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period0.480.17
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Generalised linear mixed model (GLMM) · p = <0.001 · Odds ratio (or): 4.41 · 95% CI 2.53 to 7.67The OR was obtained from GLMM model with random intercept and logit link. Treatment, visit, visit by treatment interaction and baseline were specified as fixed effects. An OR \> 1 favours SZC.
SecondaryExpected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances

The expected number of normokalemic instances is the sum of the probabilities of normokalaemic instance at each visit during the evaluation period. Normokalaemic is defined as S-K between 4.0 and 5.0 mmol/L.

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Number · Sum of probabilities
Expected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances
Sum of probabilitiesSodium Zirconium Cyclosilicate (SZC)Placebo
Expected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances1.910.70
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Mean difference (final values): 1.20 · 95% CI 0.77 to 1.64Endpoint analysed with Generalised linear mixed model. The CI for the mean difference was calculated by bootstrapping. A mean difference \> 0 favours SZC.
SecondaryInstances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period

The probability of maintaining instances of potassium gradient of \< 3.0 mmol/L was evaluated at each LIDI visit during the evaluation period, by categorisation of potassium gradient into \< 3.0 or \>=3.0 mmol/L. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.

Time frame:
Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Reported as:
Number · Probability
Instances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period
ProbabilitySodium Zirconium Cyclosilicate (SZC)Placebo
Instances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period0.520.16
Statistical analysis
  • Sodium Zirconium Cyclosilicate (SZC) vs Placebo · Generalised linear mixed model (GLMM) · p = <0.001 · Odds ratio (or): 5.82 · 95% CI 3.15 to 10.73The OR was obtained from GLMM model with random intercept and logit link. Treatment, visit, visit by treatment interaction and baseline were specified as fixed effects. An OR \> 1 favours SZC.

Adverse events

Collected over Includes adverse events that occurred from time of randomization throughout the treatment period and follow-up period, up to end of study visit (Day 71 +/- 3 days) or premature study discontinuation visit.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Zirconium Cyclosilicate (SZC)0/66 (0%)6/66 (9.1%)24/66 (36.4%)
Placebo1/67 (1.5%)8/67 (11.9%)25/67 (37.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSodium Zirconium Cyclosilicate (SZC)Placebo
Arteriovenous fistula site complicationInjury, poisoning and procedural complications0/663/67
Traumatic renal injuryInjury, poisoning and procedural complications1/660/67
SpondylolisthesisMusculoskeletal and connective tissue disorders1/660/67
Cardiac failureCardiac disorders1/660/67
SynovitisMusculoskeletal and connective tissue disorders1/660/67
Haemorrhagic gastroenteritisGastrointestinal disorders1/660/67
Cholangitis acuteHepatobiliary disorders1/660/67
PneumoniaInfections and infestations0/661/67
Arteriovenous fistula occlusionInjury, poisoning and procedural complications0/661/67
Brain stem haemorrhageNervous system disorders0/661/67
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSodium Zirconium Cyclosilicate (SZC)Placebo
HypokalaemiaMetabolism and nutrition disorders7/666/67
ConstipationGastrointestinal disorders6/662/67
Upper respiratory tract infectionInfections and infestations4/661/67
Dialysis hypotensionVascular disorders3/664/67
DizzinessNervous system disorders3/660/67
HeadacheNervous system disorders3/662/67
HypotensionVascular disorders3/663/67
AcidosisMetabolism and nutrition disorders0/663/67
HyperkalaemiaMetabolism and nutrition disorders1/663/67
Metabolic acidosisMetabolism and nutrition disorders2/663/67

Baseline characteristics

Baseline analysis was based on all patients in the full analysis set (FAS), which comprised all patients randomized. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received.

Age, Continuous
Age, Continuous(Years)Sodium Zirconium Cyclosilicate (SZC)PlaceboTotal
Mean54.9 ± 11.3254.5 ± 11.3654.7 ± 11.30
Age, Customized
Age, Customized(Participants)Sodium Zirconium Cyclosilicate (SZC)PlaceboTotal
Age group (years) — <50 years202242
Age group (years) — >=50 - <65 years333366
Age group (years) — >=65 -<85 years141125
Age group (years) — >=85 years011
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Zirconium Cyclosilicate (SZC)PlaceboTotal
Female343468
Male333366
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sodium Zirconium Cyclosilicate (SZC)PlaceboTotal
Asian6767134
08

Study locations

36 sites
  • Research Site
    Baotou, 014040, China
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 102206, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changchun, 130041, China
  • Research Site
    Dongguan, 523009, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Jinan, 250014, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210011, China
  • Research Site
    Ningbo, 315000, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200065, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200090, China
  • Research Site
    Shanghai, 200120, China
  • Research Site
    Shanghai, 200127, China
  • Research Site
    Shanghai, 200232, China
  • Research Site
    Shanghai, 200233, China
  • Research Site
    Shanghai, 200240, China
  • Research Site
    Shanghai, 201199, China
  • Research Site
    Shenzhen, 518035, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Tianjin, 300052, China
  • Research Site
    Urumqi, CN-830004, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Yinchuan, 750004, China
09

References and documents

Publications

  • Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2. PubMed 32588430 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2022, 13 months.

Results were first posted in Mar 2023, 1 year 2 months after primary completion.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2020
First posted
Jan 3, 2020
StartActual
Nov 16, 2020
Primary completionActual
Jan 3, 2022
CompletionActual
Jan 3, 2022
Results first posted
Mar 28, 2023
Last update
Mar 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04217590
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 3, 2020
Start date
Nov 16, 2020
Primary completion
Jan 3, 2022
Completion
Jan 3, 2022
Results posted
Mar 28, 2023
Last update
Mar 28, 2023

Study contacts

Zhaohui Ni
principal investigator · Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion